{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:05:38Z","timestamp":1787169938977,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NMRPG8G6102"],"award-info":[{"award-number":["NMRPG8G6102"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG8E0631"],"award-info":[{"award-number":["CMRPG8E0631"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12072-021-10159-w","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T14:02:52Z","timestamp":1614866572000},"page":"301-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation"],"prefix":"10.1007","volume":"15","author":[{"given":"Yuan-Hung","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"10159_CR1","unstructured":"World Health Organization. World Health Organization factsheets for chronic hepatitis B (Last updated July 2016). Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en Accessed February 22, 2017."},{"key":"10159_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/liv.12395","volume":"34","author":"V Calvaruso","year":"2014","unstructured":"Calvaruso V, Crax\u00ec A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int. 2014;34:85\u201390.","journal-title":"Liver Int"},{"key":"10159_CR3","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/jvh.12851","volume":"25","author":"CH Chen","year":"2017","unstructured":"Chen CH, Hsu YC, Lu SN, et al. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J Viral Hepat. 2017;25:590\u20137.","journal-title":"J Viral Hepat"},{"key":"10159_CR4","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","volume":"13","author":"CH Chen","year":"2015","unstructured":"Chen CH, Hung CH, Hu TH, et al. Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2015;13:1984\u201392.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10159_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","volume":"24","author":"CH Chen","year":"2018","unstructured":"Chen CH, Hung CH, Wang JH, Lu SN, Hu TH, Lee CM. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect. 2018;24:997\u20131003.","journal-title":"Clin Microbiol Infect"},{"key":"10159_CR6","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41598-017-02010-w","volume":"7","author":"CC Yao","year":"2017","unstructured":"Yao CC, Hung CH, Hu TH, et al. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg \u2264 200 IU\/mL. Sci Rep. 2017;7:1839.","journal-title":"Sci Rep"},{"key":"10159_CR7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/liv.13346","volume":"37","author":"DK Wong","year":"2017","unstructured":"Wong DK, Seto WK, Cheung KS, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017;37:995\u20131001.","journal-title":"Liver Int"},{"key":"10159_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2016.03.013","volume":"65","author":"T Tada","year":"2016","unstructured":"Tada T, Kumada T, Toyoda H, et al. HBcrAg predicts hepatocellular carcinoma development: an analysis using timedependent receiver operating characteristics. J Hepatol. 2016;65:48\u201356.","journal-title":"J Hepatol"},{"key":"10159_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/apt.15058","volume":"49","author":"YC Hsu","year":"2019","unstructured":"Hsu YC, Nguyen MH, Mo LR, et al. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther. 2019;49:107\u201315.","journal-title":"Aliment Pharmacol Ther"},{"key":"10159_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol int. 2012;6:531\u201361.","journal-title":"Hepatol int"},{"key":"10159_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00535-009-0017-y","volume":"44","author":"JH Wang","year":"2009","unstructured":"Wang JH, Changchien CS, Hung CH, et al. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol. 2009;44:439\u201346.","journal-title":"J Gastroenterol"},{"key":"10159_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/1469-0691.12739","volume":"20","author":"WK Seto","year":"2014","unstructured":"Seto WK, Wong DK, Fung J, et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect. 2014;20:1173\u201380.","journal-title":"Clin Microbiol Infect"},{"key":"10159_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/00365521.2018.12027892","volume":"1","author":"CM Lee","year":"2003","unstructured":"Lee CM, Chen CH, Lu SN, et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol. 2003;1:95\u2013101.","journal-title":"Scand J Gastroenterol"},{"key":"10159_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337\u201344.","journal-title":"Biometrics"},{"key":"10159_CR15","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","volume":"18","author":"TN Tseng","year":"2020","unstructured":"Tseng TN, Hu TH, Wang JH, Kuo YH, Hung CH, Lu SN, Jeng WJ, Chen CH. Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU\/mL. Clin Gastroenterol Hepatol. 2020;18:2803\u20133281.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10159_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","volume":"70","author":"B Testone","year":"2019","unstructured":"Testone B, Lebosse F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70:615\u201325.","journal-title":"J Hepatol"},{"key":"10159_CR17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/liv.13046","volume":"36","author":"N Chuaypen","year":"2016","unstructured":"Chuaypen N, Posuwan N, Payungporn S, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int. 2016;36:827\u201336.","journal-title":"Liver Int"},{"key":"10159_CR18","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/infdis\/jiv572","volume":"213","author":"M Honda","year":"2016","unstructured":"Honda M, Shirasaki T, Terashima T, et al. Hepatitis B virus (HBV) corerelated antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J Infect Dis. 2016;213:1096\u2013106.","journal-title":"J Infect Dis"},{"key":"10159_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.hepres.2006.08.005","volume":"36","author":"N Shinkai","year":"2006","unstructured":"Shinkai N, Tanaka Y, Orito E, et al. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res. 2006;36:272\u20136.","journal-title":"Hepatol Res"},{"key":"10159_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1872-034X.2011.00910.x","volume":"42","author":"A Matsumoto","year":"2012","unstructured":"Matsumoto A, Tanaka E, Suzuki Y, et al. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. Hepatol Res. 2012;42:139\u201349.","journal-title":"Hepatol Res"},{"key":"10159_CR21","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/hep.30474","volume":"70","author":"J Liu","year":"2019","unstructured":"Liu J, Li T, Zhang L, Xu A. The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian chronic hepatitis B patients: a systematic review. Hepatology. 2019;70:1045\u201355.","journal-title":"Hepatology"},{"key":"10159_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","volume":"222","author":"R Fan","year":"2020","unstructured":"Fan R, Peng J, Xie Q, et al. Combining HBV RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B patients. J Infect Dis. 2020;222:611\u20138.","journal-title":"J Infect Dis"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10159-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10159-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10159-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T03:10:52Z","timestamp":1621825852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10159-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10159"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10159-w","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"12 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuan-Hung Kuo, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, and Chien-Hung Chen declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation [Chang Gung Memorial Hospital (IRB No.: 202000171B0)] and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}